Menu
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on ...
- First patient enrolled in RE-COVERY DVT/PE™
- Involving 14,000 patients worldwide, the study will collect real-world data on reducing the risk of DVT and PE with Pradaxa®1
(BUSINESS WIRE)-- Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE). The new study will provide insights into how patients with DVT and PE are being treated in real-world clinical practice, and will add to the growing body of data on the safety and effectiveness of Pradaxa® (dabigatran etexilate) compared to warfarin. ...
Source : http://me-newswire.net//news/17407/en...
Dans la même rubrique :
Jeudi 25 Avril 2024 - 20:17 Tchad : N'Djamena et Massakory, villes les plus chaudes avec un pic de 44°C (ANAM) |
Jeudi 21 Mars 2024 - 00:54 Sûr et Sain : Naviguer dans les Méthodes de Paiement Sécurisées |
Dimanche 3 Mars 2024 - 00:58 Obtiens un pari gratuit chaque semaine avec un nouveau bonus 1xBet |
